Stem Cell use in Regenerative Medicine Analysed in New Report
Piribo, the online destination for Pharma intelligence, has added a new report.
The report “Stem Cells in Regenerative Medicine” states that large pharmaceutical companies are working with the stem cells in regenerative medicine to develop new cell therapies to will help grow their future pipelines. The study uncovers information about major life science research companies working in the stem cell field that supply key products and services to pharma and academic life science researchers working in stem cell R&D. The report reviews the sources of government and private stem cell research investment.
The report reviews what new stem cell based therapies are likely to become available in the near future. According to the 173 page report, drug makers have become interested in the potential opportunity to improve their chances for making safer future drugs by using pluripotent stem cells, such as human embryonic stem cells (hESCs) or induced pluripotent stemcells (iPSCs), as well as various kinds of adult stem cells to make customised, disease focused cells used in cell screening campaigns in drug discovery toxicity or efficacy testing. The customised human stem cell-derived cells would eliminate the need to sacrifice millions of lab animals that are currently used in drug safety testing.
View the report “Stem Cells in Regenerative Medicine”